
The future of child health: Innovations expanding access to immunization
Groundbreaking advances in medicine have made many of the world's worst diseases preventable. On May 14th, 1796, the English physician Edward Jenner carefully infected eight-year-old James Phipps with cowpox. The boy developed a fever, becoming cold and losing his appetite. But then he felt better. When James was then exposed to smallpox, the deadliest infectious disease of the time, the boy not only didn't get sick but didn't transmit the smallpox to those around him. Jenner had administered a vaccine that imitated the smallpox infection, safely teaching the boy's body how to defend itself. It was a significant step on humanity's journey to research and develop vaccines to protect against infectious diseases.
Today, immunization programs are transforming our world, having eradicated smallpox and significantly reduced the impact of many other diseases like polio, measles, and meningitis. Vaccination prevents around five million deaths every year, and has helped to halve child mortality over the past 25 years. However, infectious diseases still kill millions and children are particularly vulnerable. Among children under five, pneumonia is one of the biggest killers, while measles remains among the deadliest diseases worldwide. And infectious diseases do not respect borders: this year, Texas, USA suffered an alarming outbreak of measles, mostly among children and almost entirely among the unvaccinated.
Vaccination protects children and stops the spread of infectious diseases: The more people that are vaccinated, the safer the world becomes. Following the lead of national governments, organizations such as the WHO, UNICEF, and Gavi, the Vaccine Alliance support immunization programs reaching millions of children in some of the most hard to reach places. But recently, vaccination rates have stagnated: Coverage for the vaccine that protects against diphtheria, tetanus, and pertussis - the measure of basic childhood immunization- stalled at around 84 percent in 2023. The ideal is to make vaccines available to everyone, and especially to the most vulnerable children in regions where infectious diseases are most prevalent. And as Jenner's work drove forward the development of the first vaccines, pioneering new innovations are now driving ever more effective, efficient, and equitable access to vaccination. In the 200 years since vaccinations were developed, they have saved many millions of lives protecting people from infectious diseases including smallpox, measles, and meningitis. Photograph by Junior Diatezua Kannah © Gates Archive
Remarkably, protection against some diseases can now begin before birth by vaccinating pregnant mothers— the vaccine stimulates an immune response in the pregnant mother, who passes protective antibodies to the baby, protecting them from the moment they are born. Such 'maternal vaccination' is widely used to protect newborn babies from tetanus and flu, and new developments have also made it possible for respiratory syncytial virus (RSV). Common among infants, RSV causes breathing difficulties and is the most common cause of pneumonia in infants younger than six months old. After decades of research, a new maternal vaccine for RSV has been developed and will be available to lower-income countries where it is most needed- helping to reduce the 3.6 million hospitalizations and 100,000 deaths in children under five caused by RSV.
Thanks to pioneering scientific research, vaccines are now available for more than 30 life-threatening diseases and infections. To maximize the opportunity this brings, it is key to work with countries and partners to efficiently expand global access to these life-saving tools. The new hexavalent vaccine plays a crucial role in this. It combines protection against six deadly diseases in a single vaccine, protecting a child against diphtheria, tetanus, pertussis, Haemophilus influenzae B, hepatitis B, and polio. Reducing the number of injections makes it easier for children to get their full slate of immunizations and reduces burden on caregivers, healthcare workers, and overstretched healthcare systems. Immunization programmes reach people even in the most challenging places, saving millions of lives each year. Photograph by Dominique Catton © Gates Archive
Another way researchers are working to expand access is by exploring a simpler way of administering vaccines using microneedle array patches (MAPs). About the size of a small bandage, a single-use MAP is applied to the skin where many microscopic needles deliver the vaccine into the body. It only takes minutes, and unlike traditional injections, administering a MAP may not require a highly trained health worker—it could be given by volunteers. Early trials in The Gambia have shown these patches can deliver the measles-rubella vaccines to adults, toddlers, and infants as safely and effectively as syringes.
Key to ensuring a vaccine's efficacy is the cold chain, a network of refrigerators, freezers, and cold storage boxes that keep vaccines at the right temperature as they travel. With vaccines highly sensitive to temperature, the value of a little sticky label called a VVM cannot be overstated. VVMs, short for vaccine vial monitors, are heat-sensitive stickers that change color with cumulative exposure to heat. They enable health professionals to see at a glance when a vaccine should not be used. A microneedle contraceptive patch on display at an exhibition at the Gates Foundation in Seattle. Innovations including the use of microneedle patches are making vaccination easier and more accessible. Photograph by Brandon Hill © Gates Foundation A manager inspects vaccines held in a cold storage room in Somalia. The cold chain is a vital network of refrigerators, freezers, and cold boxes that keep heat-sensitive vaccines at the optimum temperature on their journey from pharmaceutical production to health worker in the field. Photograph by Ismail Taxta © Gates Archive
But when a vaccine's end destination lacks reliable electricity for refrigeration, the Solar Direct-Drive (SDD) refrigerator is rising to the challenge. It not only harnesses solar energy to keep vaccines at the right temperature but also stores excess energy to keep running through sunless days. For many communities they can be transformational: in Kenya's Makueni County, the installation of an SDD refrigerator doubled the vaccination rate for children.
In the garden of Edward Jenner's home, now a museum, is an eccentric-looking thatched summerhouse that he named his Temple of Vaccinia. Here, Jenner worked tirelessly to provide free vaccinations. It is fitting that the father of immunization never sought to profit from his efforts and was committed to equitable vaccination, because that's what it takes to prevent infectious diseases from spreading. Through the collaborative efforts of health workers, governments, and organizations, adequately funding critical immunization programs, and harnessing the power of science and innovation, progress is possible—bringing the world closer to ending preventable child deaths.
Find more life-saving innovations here.
More on vaccination innovations here.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Miami Herald
5 hours ago
- Miami Herald
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, comments on the extension of the MPox Public Health Emergency of International Concern (PHEIC) by WHO. The Director General of WHO has extended the PHEIC declaration for MPox epidemic according to a WHO news release dated July 10, 2025, following continuing upsurge of the MPox virus (MPXV) epidemics in the African region[1]. Sporadic travel related cases of MPXV Clade I have occurred outside Africa, including in the USA, but so far have not resulted in further transmission. The threat of such sustained transmission continues, and is part of the decision to continue the PHEIC status. "Our development of NV-387 towards Phase II clinical trial for treatment of MPOX is timely for responding to the continuing threat of a global spread of MPox, and for meeting the need for treatment of MPox patients in Africa, in light of the continuing spread of MPox," said Anil R. Diwan, PhD, President and Executive Chairman of NanoViricides, Inc., adding, "If successful, this NV-387 clinical trial will also open up a multi-billion-dollar global market of preparedness for poxvirus bioterrorism to us." At present, there is no drug approved, that is actually safe and effective in humans, for the treatment of the MPox disease, which is caused by MPXV infection. Tecovirimat (SIGA) has failed to show any effectiveness over standard of care in a clinical trial for treatment of MPXV infections. Brincidofovir treatment resulted in drug-induced liver disease in three out of three treated MPox patients resulting in cessation of therapy, and did not show any effectiveness in these patients according to a peer reviewed "retrospective observational study" also called "non-randomized study"[2], [3]. In spite of this, a clinical trial of brincidofovir for treating MPox was initiated under an international coalition led by US CDC and first patient was dosed around January 2025 in this "MOSA" clinical trial[4]. The topline results from this clinical trial regarding safety and efficacy were anticipated by CY Q2 (i.e. June, 2025). We have not found any press releases announcing any such results. The orthopoxviruses can escape both small chemical drugs, tecovirimat and brincidofovir, by mutations, according to peer reviewed scientific articles[5]. The above factors clearly highlight the need for an effective therapeutic for the treatment of MPOX. In contrast to the small chemical drugs, vaccines, antibodies, that viruses escape readily, NV-387, the novel broad-spectrum antiviral developed by the Company, is designed such that viruses would not escape the drug. This is because NV-387 mimics the cell-side feature called heparan sulfate proteoglycans (HSPG) to which the viruses bind and concentrate next to the cell before they can attack the cell and cause infection. No matter how much a human pathogenic virus mutates, it continues to bind to HSPG. Over 90% of human pathogenic viruses are known to bind to HSPG. Additionally, NV-387 has been found to be extremely safe and well tolerated in a Phase I human clinical trial. There were no reported adverse events or serious adverse events in this clinical trial. In animal studies, NV-387 was found to be extremely safe, with a No-Observed-Adverse-Event Level (NOAEL) of the drug at 1,200 mg/kg, and the Maximum Tolerated Dose (MTD) at 1,500 mg/kg in intravenous injection in rats. The Phase I clinical trial results for NV-387 were consistent with the safety observations in animal model studies. NV-387 is orally available and is formulated as oral gummies that are soft solids that do not require swallowing, and are designed to dissolve in the oral cavity itself. This is important because MPox patients may not have the ability to swallow pills or capsules because of viral lesions in the oral cavity. The Company recently announced that it has completed the development of a clinical trial protocol for the impending Phase II study of NV-387 for the treatment of MPox disease in the African Region. This will be a randomized clinical trial comparing NV-387 treatment with the Standard of Care, to evaluate the dosing regimen for NV-387, the safety and tolerability of the dosing regimen in MPox patients, and effectiveness of NV-387 on the MPXV virus and the MPox disease that it causes. Of note, both tecovirimat and brincidofovir were approved by the US FDA for smallpox virus, based on the "Animal Rule", which avoids the use of human efficacy clinical trials that would be unethical to conduct with a smallpox challenge study in humans. We also note that smallpox is a more severe disease than even the most severe form of MPox disease, and both of these drugs have been found to be inadequate for the treatment of MPox according to currently available datasets (although definitive data from the brincidofovir clinical trial has not been released yet). These two drugs (tecovirimat and brincidofovir) have been acquired in the US Strategic National Stockpile for bioterrorism preparedness to the tune of around billion dollars. The overall global market for bioterrorism preparedness against smallpox variants is estimated to be several billions of dollars. The Company anticipates that a successful Phase II clinical trial of NV-387 for the treatment of MPox would open up the US Government SNS market and similar global markets to our drug and benefit the Company's other programs as well. MPXV Clade Ib strain is dominant in major parts of Africa and continues to spread, whereas the less virulent MPXV Clade IIb strain is dominant in Sierra Leone, with cases increasing at present. While vaccination has started, overall, the uptake of available vaccines has remained lower than anticipated due to logistical, operational, and financial barriers, according to the report of the International Health Regulations (2005) (IHR) Emergency Committee for MPox of the WHO on June 5, 2025. MPXV Clade II has become epidemic, within limited population demographics, in the Western world including the USA since a 2022 epidemic it caused, driven by travel-related transfer from Western Africa. The PHEIC regarding MPox 2024 was first declared on August 14, 2024, and was extended in February 2025. It has been extended again now as the MPXV continues to spread in neighboring countries in Africa threatening further global spread and sustained transmission. ABOUT NANOVIRICIDES NanoViricides, Inc. (the "Company") ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development. Contact:NanoViricides, Public Relations Contact:ir@


Business Wire
5 hours ago
- Business Wire
Hippocratic AI and Sheba Medical Center Partner to Transform Patient Care with Generative AI Integration
PALO ALTO, Calif. & RAMAT GAN, Israel--(BUSINESS WIRE)--Hippocratic AI, the global leader and pioneer in generative AI healthcare agents, today announced a partnership with Sheba Medical Center, a global beacon of medical innovation and research ranked by Newsweek as one of the top ten hospitals in the world. The partnership brings together Hippocratic AI's leading AI agent technology and Sheba's internationally acclaimed ARC (Accelerate, Redesign, Collaborate) Innovation Center to deploy safe, effective, and scalable AI solutions that transform healthcare delivery. Additionally, Hippocratic AI will join the ARC ecosystem, which is a global network consisting of leading hospitals, researchers, and innovation organizations. This ecosystem opens the door to new potential pathways for meaningful impact with others in the network. Hippocratic AI and Sheba are collaborating to advance their shared vision of creating a future of healthcare abundance by expanding access, enhancing quality, and improving the patient experience with empathetic, clinically rigorous AI that is both safe and effective. To date, healthcare providers have used Hippocratic AI GenAI healthcare agents to complete more than 2.49 million patient calls, earning an average patient satisfaction rating of 8.95 out of 10. 'Partnering with Sheba is an important step forward in realizing our mission to deliver safe, effective, high-quality generative AI healthcare at scale,' said Munjal Shah, Co-Founder and CEO of Hippocratic AI. 'Sheba's strong reputation for clinical excellence, and its innovation ecosystem at ARC make it the perfect partner to help us deliver transformative AI tools to providers and patients worldwide.' As part of its institutional vision to redefine the future of medicine, Sheba Medical Center is helping to drive the global shift toward AI-powered healthcare. Sheba combines clinical excellence with system-wide innovation, aiming to integrate safe, effective, and compassionate AI into real-world care at scale. This partnership with Hippocratic AI is part of Sheba's broader effort to become a fully AI-enabled health system and serve as a model for integrated responsible, patient-centered innovation. At the heart of this innovation is Sheba's ARC Innovation Center, a multidisciplinary model designed to transform healthcare by uniting clinicians, entrepreneurs, and researchers. Through this partnership, Hippocratic AI will integrate its generative AI agents to support non-diagnostic, patient-facing roles into Sheba's live clinical and research environments. Initial areas of collaboration include, but are not limited to, triage and patient intake. The agents will initially launch in English, followed by Hebrew in a later phase. With Sheba Medical Center recognized as one of the leading health systems in the Middle East, it serves as a global destination for patients seeking advanced, high-quality care. Sheba receives patients from both the region, including Jordan and Egypt, and beyond, delivering trusted, personalized treatment across a broad range of specialized services. Both organizations are guided by deeply aligned missions and values. Sheba's institutional mission is to deliver world-class medical care to all, regardless of background, religion, or nationality and to lead the way in cutting-edge research, innovation, and compassionate treatment. Its values include inclusivity, humanitarianism, and global impact. These principles align with Hippocratic AI's values to Do No Harm, Patients First, and providing Equal Access for All. "AI is transforming global health, and our partnership with Hippocratic AI supports Sheba's mission to become a fully AI-powered hospital," said Prof. Eyal Zimlichman, Founder and Director of ARC, and Chief Innovation, Transformation, and AI Officer at Sheba Medical Center. "Together, we are not just piloting a technology, but reimagining the way care is delivered – building a new clinical reality where intelligent, human-aligned systems work hand-in-hand with caregivers to elevate the standard of care worldwide." About Hippocratic AI Hippocratic AI has developed a safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Stanford, Microsoft, Google, and NVIDIA. Hippocratic AI has received a total of $278 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, NVIDIA's NVentures, Premji Invest, SV Angel, and six health systems. For more information on Hippocratic AI, About Sheba Medical Center The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation. Sheba's City of Health unities specialty hospitals, research and simulation centers, a virtual hospital, and ARC (Accelerate, Redesign, Collaborate), its innovation arm which connects entrepreneurs and clinicians to advance the development and implementation of new AI and tech solutions in healthcare, and accelerates the adoption of innovation both within the hospital and in health systems worldwide. Sheba is one of the top-ten hospitals in the world, having been ranked a World's Best Hospital by Newsweek for the last seven consecutive years (2019-2025). For more information, visit: or


Time Business News
5 hours ago
- Time Business News
Innovative Frontiers in Artemisinin Combination Therapy
To increase efficacy and reduce the risk of drug resistance, artemisinin combination therapy (ACT) treats malaria by mixing an artemisinin-based molecule with one or more fellow drugs. Artemisinin Combination Therapy (ACT) has expanded considerably due to high malaria burden in Southeast Asia and sub-Sahara Africa in the market due to its effectiveness against high malaria burden and drug-resistant Plasmodium Falciparum. Global health initiatives such as WHO guidelines and funding support have improved access and strength. The ongoing drug progress has also increased treatment efficacy and adherence to the patient, collectively increased market growth. Key Growth Drivers and Opportunities Urgent Demand for More Effective Malaria Treatments: A major trend that runs the future of the market is required for more effective malaria remedies between persistent cases and increasing drug resistance. It is promoting innovation in ACT formulations to develop rapid acting, long lasting, and more patient -friendly options. With increased government and international health funding, this progress is improving access and distribution in malaria-sustainable regions, the situation serves as a central solution in the global fight against malaria and promotes strong market development. Challenges Artemisinin combination therapy (ACT) faces boundaries due to the emergence of artemisinin-resistant malaria strains in the market, especially in parts of Southeast Asia. Additionally, inconsistent supply chains, high dependence on donor funding, and limited healthcare infrastructure in some spatial regions obstruct wide access. The need for constant innovation to be ahead of regulator challenges and resistance also leads to the ongoing obstacles for market stability and development. Innovation and Expansion Breakthrough A Treatment for Malaria Without Artemisinin Gives Children Hope In November 2024, Positive findings from KALUMI, a Phase 2 study of a new, non-artemisinin malaria medication combination being developed with Novartis and MMV, have been announced by the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM2) consortium. Given that partial resistance to artemisinin derivatives throughout Africa jeopardizes efforts to eradicate the illness, this is a significant advancement in the fight against malaria. The effectiveness and safety of a combination of lumefantrine, reformulated for once-daily dosage, and ganaplacide, a new drug, were assessed in the KALUMI trial. This novel combination was tested against artemether-lumefantrine, the most popular artemisinin-based combination therapy (ACT) for treating uncomplicated malaria in Africa. Fosun Pharma Acquires USD 3.5M to Promote the Development of Malaria Treatments In December 2023, The Japanese Global Health Innovative Technology (GHIT) Fund has awarded Y500m (USD 3.3m) to China-based Fosun Pharma to further the development of a triple artemisinin combination medication for the treatment of malaria. Artemether, lumefantrine, and amodiaquine are the three antimalarial medications that make up the triple artemisinin combination medication, which comes in a fixed dosage format. The money used to support the Phase III research that looks into the combo treatment. Fosun, the Japanese investment firm Marubini, the Thailand-based research partnership of the universities Mahidol-Oxford Tropical Medicine Research Unit (MORU), and the product development partnership Medicines for Malaria Venture (MMV) will all work together to undertake the III trial. Novartis Provides One Billion Antimalarial Treatment Courses Globally In May 2021, Novartis declared that since 1999, it has provided one billion antimalarial therapy sessions. Over 90% of this artemisinin-based combination treatment (ACT) was given to malaria-endemic nations worldwide at no profit. The most lethal kind of malaria, P. falciparum, which accounts for more than 99% of cases in Africa and half of those in Asia, is treated with ACTs as the standard of care2. ACTs have revolutionized the treatment of malaria since the turn of the century and helped to significantly lower the number of malaria-related fatalities. Inventive Sparks, Expanding Markets Among the leading companies for artemisinin combination therapy are Novartis AG, Cipla, Bliss GVS, and KPC Pharmaceuticals, Inc. The artemisinin combination therapy (ACT) firm is focusing on developing more effective and affordable formulations, such as drug-resistant and kid-safe variants, in order to enhance treatment outcomes and accessibility. Working with governments and international health organizations is another important strategy to expand distribution in malaria-endemic areas. To ensure consistent availability, local production and supply linkages are also reinforced. These programs support global efforts to eradicate malaria, combat medication resistance, and improve patient compliance. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS